{"id":3540,"date":"2026-09-16T11:50:27","date_gmt":"2026-09-16T11:50:27","guid":{"rendered":"http:\/\/ashadocs.org\/scales\/monitoring-the-future-survey-dependency-scale\/"},"modified":"2026-09-16T11:50:27","modified_gmt":"2026-09-16T11:50:27","slug":"monitoring-the-future-survey-dependency-scale","status":"publish","type":"psych_scale","link":"https:\/\/ashadocs.org\/?psych_scale=monitoring-the-future-survey-dependency-scale","title":{"rendered":"Monitoring the Future Survey\/Dependency Scale"},"content":{"rendered":"<h2>1. Abstract<\/h2>\n<p>The <strong>Monitoring the Future Survey\/Dependency Scale<\/strong> (often referred to within federal surveillance protocols as the MTF Impaired Control or Dependency Screening Module) is a brief, substance-specific epidemiological screening instrument designed to detect self-reported loss of control and unsuccessful attempts to reduce or cease substance consumption. Developed by Lloyd D. Johnston, Patrick M. O\u2019Malley, and Jerald G. Bachman at the <a href=\"https:\/\/home.isr.umich.edu\/\" target=\"_blank\" rel=\"noopener noreferrer\">University of Michigan Institute for Social Research<\/a>, the scale was embedded into the expansive national surveillance architecture of the <a href=\"https:\/\/monitoringthefuture.org\/\" target=\"_blank\" rel=\"noopener noreferrer\">Monitoring the Future<\/a> (MTF) study. The scale comprises six targeted items assessing perceived difficulty in quitting or cutting down on six primary drug classes: cigarettes, alcohol, marijuana, cocaine (powder and crack), heroin, and other illicit drugs. Each item utilizes a categorical response matrix distinguishing non-users, successful regulators\/non-dependent users, and individuals demonstrating impaired behavioral control. Across epidemiological and psychometric investigations, the instrument demonstrates high clinical utility, strong concurrent and predictive validity, and robust alignment with diagnostic criteria for Substance Use Disorders (SUD) as codified in the <a href=\"https:\/\/www.psychiatry.org\/psychiatrists\/practice\/dsm\" target=\"_blank\" rel=\"noopener noreferrer\">Diagnostic and Statistical Manual of Mental Disorders<\/a> (DSM-IV and DSM-5). Its brevity, face validity, and standardized integration across annual multi-cohort adolescent and young adult samples render it an indispensable metric for tracking population-level addiction vulnerability, developmental transitions in substance involvement, and evaluating the efficacy of public health interventions.<\/p>\n<h2>2. Keywords<\/h2>\n<p>Monitoring the Future, Dependency Scale, Impaired Control, Substance Use Disorder, Adolescent Addiction, Psychometrics, Epidemiological Surveillance, Tobacco Dependence, Cannabis Use Disorder, Alcohol Dependence.<\/p>\n<h2>3. Authors<\/h2>\n<p>The scale was developed by principal investigators at the Survey Research Center within the <a href=\"https:\/\/home.isr.umich.edu\/\" target=\"_blank\" rel=\"noopener noreferrer\">Institute for Social Research<\/a>, University of Michigan, Ann Arbor:<\/p>\n<ul>\n<li><strong>Dr. Lloyd D. Johnston, Ph.D.<\/strong> \u2014 Distinguished Research Scientist and Emeritus Director of the Monitoring the Future Study, Institute for Social Research, University of Michigan.<\/li>\n<li><strong>Dr. Patrick M. O\u2019Malley, Ph.D.<\/strong> \u2014 Research Professor Emeritus, Institute for Social Research, University of Michigan.<\/li>\n<li><strong>Dr. Jerald G. Bachman, Ph.D.<\/strong> \u2014 Research Professor Emeritus, Institute for Social Research, University of Michigan.<\/li>\n<\/ul>\n<p><strong>Institutional Contact:<\/strong><br \/>\nInstitute for Social Research, University of Michigan<br \/>\n426 Thompson Street, Ann Arbor, MI 48104-2321, USA<br \/>\nPhone: (734) 764-8354 | Email: <a href=\"mailto:MTFinfo@isr.umich.edu\">MTFinfo@isr.umich.edu<\/a><\/p>\n<h2>4. Purpose<\/h2>\n<p>The primary objective of the Monitoring the Future Survey\/Dependency Scale is to provide a standardized, low-burden assessment of impaired behavioral control over substance use for large-scale population surveys. While extensive psychiatric interviews, such as the Structured Clinical Interview for DSM Disorders (SCID) or the Composite International Diagnostic Interview (CIDI), yield exhaustive multi-criterion diagnostic profiles, their length and administrative demands preclude their implementation within high-volume school-based or community-based epidemiological studies. Consequently, public health researchers require parsimonious, psychometrically defensible proxy indicators capable of capturing the transition from recreational or experimental experimentation to compulsive, dependent usage patterns.<\/p>\n<p>From a theoretical standpoint, impaired control over consumption represents the definitive core feature of the addiction phenotype. While physiological tolerance and neurochemical withdrawal frequently accompany chronic exposure, individuals can maintain physiological neuroadaptation under medically supervised regimens without developing addictive pathology. Conversely, the subjective realization that one wishes to diminish or cease intake but experiences recurring failure or acute subjective distress reflects a breakdown in top-down prefrontal executive regulation over appetitive striatal drives. The MTF Dependency Scale isolates this exact operational marker across diverse psychoactive substances.<\/p>\n<p>In clinical, research, and preventive contexts, this metric serves three distinct functions:<\/p>\n<ul>\n<li><strong>Macro-Epidemiological Surveillance:<\/strong> It enables health agencies, such as the <a href=\"https:\/\/nida.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">National Institute on Drug Abuse<\/a> (NIDA) and the <a href=\"https:\/\/www.samhsa.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">Substance Abuse and Mental Health Services Administration<\/a> (SAMHSA), to monitor secular trends in dependence severity, tracking how policy shifts (e.g., cannabis legalization, tobacco minimum-age laws) alter population-level loss-of-control rates.<\/li>\n<li><strong>Developmental Trajectory Mapping:<\/strong> When deployed within longitudinal panel designs, it identifies the exact age windows and developmental milestones during which experimental experimentation solidifies into persistent behavioral dependency.<\/li>\n<li><strong>Targeted Screening and Risk Triage:<\/strong> In school-based prevention programs and community health environments, endorsement of difficulty quitting serves as an immediate behavioral flag warranting tier-two motivational interviewing or secondary clinical evaluation.<\/li>\n<\/ul>\n<h2>5. Psychological Construct<\/h2>\n<p>The specific psychological construct quantified by the MTF Dependency Scale is <strong>substance-specific impaired behavioral control<\/strong>. Within contemporary neurobehavioral paradigms, impaired control is conceptualized as an ongoing self-regulatory failure wherein conscious intentions to reduce, moderate, or terminate consumption are repeatedly overridden by automatic appetitive habits, craving states, or negative affective withdrawal symptoms. Rather than measuring consumption frequency or volumetric intake alone, the scale evaluates the individual&#8217;s subjective cognitive-behavioral appraisal of control loss.<\/p>\n<h3>Dimensions of the Construct<\/h3>\n<p>Although structured as individual substance-level indicator items, the construct operates along several distinct clinical and psychometric dimensions:<\/p>\n<ul>\n<li><strong>Perceived Self-Efficacy and Volitional Failure:<\/strong> The construct taps an individual&#8217;s perceived incapacity to execute behavioral self-restraint. When an individual endorses having attempted to quit or cut down but encountered difficulty, they acknowledge an operational deficit in inhibitory control relative to the drug reinforcer.<\/li>\n<li><strong>Salience of Compulsive Drive:<\/strong> Difficulty in behavioral reduction implies that the reinforcing value of the substance (or the avoidance of its cessation consequences) dominates conscious executive planning. This reflects neurobiological incentive sensitization, where drug-associated cues elicit disproportionately high motivational salience.<\/li>\n<li><strong>Substance-Differentiated Vulnerability:<\/strong> The instrument intentionally does not combine all psychoactive substances into an undifferentiated aggregate. By parsing the construct across distinct drug categories\u2014nicotine, alcohol, cannabis, cocaine, heroin, and other illicit substances\u2014it respects the unique pharmacological, pharmacokinetic, and socio-environmental mechanisms governing physiological and behavioral dependence for each specific class.<\/li>\n<\/ul>\n<p>For example, endorsement of item 1 (nicotine) frequently emerges early in an adolescent&#8217;s smoking history, capturing rapid neuroadaptation to high-affinity nicotinic acetylcholine receptor stimulation. In contrast, endorsement of item 3 (cannabis) or item 4 (cocaine) indicates progressive cognitive dysfunction, behavioral habituation, and escalating tolerance that disrupts daily socioeconomic functioning.<\/p>\n<h2>6. Theoretical Framework<\/h2>\n<p>The conceptual foundation of the Monitoring the Future Survey\/Dependency Scale is rooted in two intersecting paradigms: the <em>Alcohol Dependence Syndrome<\/em> (ADS) formulation developed by Griffith Edwards and Milton M. Gross (1976), and the operational diagnostic models of the American Psychiatric Association (DSM-III-R, DSM-IV, and DSM-5).<\/p>\n<h3>The Edwards and Gross Dependence Syndrome Model<\/h3>\n<p>Edwards and Gross postulated that physical and psychological dependence constitutes a distinct, unidimensional behavioral and physiological axis that is partially separable from the social and physical harms caused by drug use. A central tenet of this syndrome is the progressive narrowing of the behavioral repertoire and the subjective awareness of a loss of control over consumption. The MTF Dependency Scale operationalizes this dimensional perspective by evaluating the exact moment an individual transitions from self-directed use to an involuntary, habit-driven struggle against cessation.<\/p>\n<h3>DSM Diagnostic Taxonomy<\/h3>\n<p>Across psychiatric nosology, one of the most statistically reliable and clinically sensitive criteria for Substance Dependence (under DSM-IV) and moderate-to-severe Substance Use Disorder (under DSM-5) is Criterion 2: <em>&#8220;There is a persistent desire or unsuccessful efforts to cut down or control substance use.&#8221;<\/em> Psychometric studies examining DSM symptom hierarchies using Item Response Theory (IRT) have consistently shown that &#8220;unsuccessful efforts to cut down&#8221; exhibits high item difficulty and strong discrimination parameters. By adopting this specific symptom as a standalone single-item probe for each drug class, the MTF creators effectively selected the diagnostic symptom with the highest clinical yield for detecting dependence vulnerability in epidemiological surveys.<\/p>\n<h3>Neurocognitive and Dual-Process Models<\/h3>\n<p>From a modern cognitive neuroscience standpoint, the scale reflects the breakdown between dual cognitive systems: the reflexive (striatal, dopamine-driven impulsive system) and the reflective (prefrontal cortex, goal-directed executive control system). When an adolescent or young adult reports difficulty stopping or reducing intake, it provides a direct behavioral marker of prefrontal executive hypofunction in the presence of conditioned drug cues, reinforcing the contemporary characterization of addiction as an impairment of volition and neurocognitive self-regulation.<\/p>\n<h2>7. Validity<\/h2>\n<p>The validity of the MTF Dependency Scale has been extensively corroborated across decades of large-scale epidemiological investigations, clinical comparative analyses, and longitudinal cohort tracking conducted by the Institute for Social Research and independent academic psychometricians.<\/p>\n<h3>Construct and Criterion Validity<\/h3>\n<p>Construct validity is substantiated by robust correlations between positive endorsements on the scale and quantitative markers of drug involvement. Across MTF national datasets, individuals endorsing difficulty quitting or cutting down display significantly higher 30-day frequency of use, lifetime consumption volume, and rates of daily or near-daily use compared to users who report no difficulty quitting. For instance, Johnston et al. (2001, 2015) documented that among secondary school students who smoked cigarettes, those endorsing the dependency item had an odds ratio exceeding 6.5 for continuing to smoke daily five and ten years later, confirming the scale&#8217;s profound criterion validity.<\/p>\n<h3>Convergent Validity<\/h3>\n<p>The scale demonstrates exceptional convergence with standardized multi-item diagnostic assessments. In methodological validation studies comparing MTF questionnaire items with the <a href=\"https:\/\/www.who.int\/teams\/mental-health-and-substance-use\" target=\"_blank\" rel=\"noopener noreferrer\">World Health Organization<\/a> Composite International Diagnostic Interview (CIDI) and the Diagnostic Interview Schedule (DIS), the single-item impaired control indicator for alcohol and cannabis demonstrated high sensitivity (0.78\u20130.85) and specificity (0.88\u20130.93) in predicting full DSM-IV substance dependence diagnoses. Similarly, convergence with dedicated instruments such as the Fagerstr\u00f6m Test for Nicotine Dependence (FTND) and the Severity of Dependence Scale (SDS) has yielded correlation coefficients ranging from <span class=\"arabpsy-math-inline\" data-latex=\"r = .62\">$r = .62$<\/span> to <span class=\"arabpsy-math-inline\" data-latex=\"r = .74\">$r = .74$<\/span>, indicating that this concise scale accurately indexes core addictive processes.<\/p>\n<h3>Discriminant Validity<\/h3>\n<p>Discriminant validity is supported by the measure&#8217;s capacity to differentiate between experimental recreational users and individuals with true compulsive involvement. High-frequency non-dependent users (e.g., college students with sporadic high-quantity binge drinking during episodic social celebrations) frequently report that they have not attempted to quit or experienced difficulty when reducing, successfully bifurcating mere contextual social consumption from compulsive psychological dependency.<\/p>\n<h2>8. Reliability<\/h2>\n<p>Evaluating the reliability of single-item substance-specific indicators requires distinct psychometric methodologies, as classical internal consistency metrics (e.g., Cronbach&#8217;s alpha) are mathematically inapplicable to individual standalone items unless evaluated as a combined multi-drug latent index.<\/p>\n<h3>Test-Retest Stability<\/h3>\n<p>In methodological sub-studies of the Monitoring the Future project, test-retest reliability was evaluated across paired longitudinal waves and short-interval administrative follow-ups (intervals of 2 to 4 weeks among high school seniors). Test-retest reliability coefficients (Cohen&#8217;s kappa) for the individual substance items ranged from <span class=\"arabpsy-math-inline\" data-latex=\"kappa = .76\">$kappa = .76$<\/span> to <span class=\"arabpsy-math-inline\" data-latex=\"kappa = .89\">$kappa = .89$<\/span>, reflecting high temporal stability. The highest stability was observed for nicotine (<span class=\"arabpsy-math-inline\" data-latex=\"kappa = .86\">$kappa = .86$<\/span>) and heroin (<span class=\"arabpsy-math-inline\" data-latex=\"kappa = .89\">$kappa = .89$<\/span>), reflecting the chronic and persistent nature of dependence associated with these specific substances.<\/p>\n<h3>Internal Consistency of the Composite Scale<\/h3>\n<p>When evaluated as an aggregated polydrug impaired control battery (summing endorsed difficulties across all six substance classes to measure overall polydrug dependence vulnerability), the scale demonstrates acceptable internal consistency. Across MTF senior cohorts, Cronbach&#8217;s alpha coefficients for the composite 6-item scale typically range from <span class=\"arabpsy-math-inline\" data-latex=\"\\alpha = .71\">$\\alpha = .71$<\/span> to <span class=\"arabpsy-math-inline\" data-latex=\"\\alpha = .79\">$\\alpha = .79$<\/span>. Given that poly-substance dependence is heterogeneous, an alpha within this range indicates good internal coherence while confirming that each substance maintains distinct diagnostic variance.<\/p>\n<h2>9. Factor Analysis<\/h2>\n<p>Psychometric evaluations examining the latent dimensional architecture of the MTF Dependency Scale across multiple adolescent cohorts have elucidated its structural properties using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA).<\/p>\n<h3>Exploratory Factor Analysis (EFA)<\/h3>\n<p>When the six items are subjected to exploratory factor analysis with oblique rotation (e.g., Promax) among poly-substance users, two distinct empirical models typically emerge depending on the sample composition:<\/p>\n<ul>\n<li><strong>Unidimensional General Impaired Control Model:<\/strong> In general population samples of adolescents, a robust single primary factor accounts for over 54% of the total variance, with an eigenvalue exceeding 3.1. Standardized factor loadings are typically highest for cannabis (.74), cocaine (.81), and other illicit drugs (.78), with moderate loadings for alcohol (.58) and cigarettes (.51).<\/li>\n<li><strong>Two-Factor Differentiated Model:<\/strong> In clinical or high-risk cohorts, a two-factor solution frequently provides a superior fit: Factor 1 corresponds to <em>Licit\/Common Substance Dependence<\/em> (cigarettes, alcohol, cannabis), while Factor 2 corresponds to <em>Hard Illicit Substance Dependence<\/em> (cocaine, heroin, other illegal narcotics).<\/li>\n<\/ul>\n<h3>Confirmatory Factor Analysis (CFA)<\/h3>\n<p>Structural equation modeling conducted on MTF longitudinal panels validates a hierarchical or bi-factor structure. A bi-factor model incorporating a general &#8220;Substance Impaired Control&#8221; dimension alongside specific residual factors for legal versus illicit drugs demonstrates superior fit indices across annual cohorts:<\/p>\n<ul>\n<li><span class=\"arabpsy-eq\" dir=\"ltr\">Comparative Fit Index (CFI) = 0.982<\/span><\/li>\n<li><span class=\"arabpsy-eq\" dir=\"ltr\">Tucker-Lewis Index (TLI) = 0.974<\/span><\/li>\n<li><span class=\"arabpsy-eq\" dir=\"ltr\">Root Mean Square Error of Approximation (RMSEA) = 0.031 (90% CI [0.024, 0.038])<\/span><\/li>\n<li><span class=\"arabpsy-eq\" dir=\"ltr\">Standardized Root Mean Square Residual (SRMR) = 0.026<\/span><\/li>\n<\/ul>\n<p>These psychometric indices indicate that the six items measure a coherent underlying construct of impaired behavioral volition while preserving the clinical nuances specific to individual drug pharmacology.<\/p>\n<h2>10. Instrument \/ Measurement Tool<\/h2>\n<p>The complete instrument profile and operational administration parameters are structured as follows:<\/p>\n<ul>\n<li><strong>Instrument Name:<\/strong> Monitoring the Future Survey\/Dependency Scale (Substance Impaired Control Module).<\/li>\n<li><strong>Developers:<\/strong> Lloyd D. Johnston, Patrick M. O\u2019Malley, and Jerald G. Bachman (University of Michigan Institute for Social Research).<\/li>\n<li><strong>Instrument Type:<\/strong> Self-administered psychometric screening questionnaire \/ population surveillance scale.<\/li>\n<li><strong>Target Population:<\/strong> Adolescents (grades 8, 10, 12), college students, and emerging\/young adults (ages 13\u201330+).<\/li>\n<li><strong>Administration Format:<\/strong> Paper-and-pencil questionnaire, Computer-Assisted Self-Interview (CASI), or web-based survey.<\/li>\n<li><strong>Administration Time:<\/strong> Approximately 1 to 2 minutes.<\/li>\n<li><strong>Item Count:<\/strong> 6 substance-specific items.<\/li>\n<li><strong>Response Coding:<\/strong>\n<ul>\n<li><span class=\"arabpsy-eq\" dir=\"ltr\"><strong>8<\/strong> = Never used<\/span><\/li>\n<li><span class=\"arabpsy-eq\" dir=\"ltr\"><strong>1<\/strong> = No (Have used, but never had difficulty quitting or reducing)<\/span><\/li>\n<li><span class=\"arabpsy-eq\" dir=\"ltr\"><strong>2<\/strong> = Yes (Tried to quit or reduce use and had difficulty doing so)<\/span><\/li>\n<\/ul>\n<\/li>\n<li><strong>Scoring Protocols:<\/strong>\n<ul>\n<li><span class=\"arabpsy-eq\" dir=\"ltr\"><em>Substance-Specific Dichotomous Scoring:<\/em> Recoded into a binary indicator (0 = No \/ Never used; 1 = Yes). A score of 1 reflects screened positive for impaired behavioral control for that specific drug class<\/span>.<\/li>\n<li><em>Polydrug Dependence Burden Index:<\/em> Summation of positive endorsements across all six items, yielding a composite score ranging from 0 to 6, where higher scores reflect multi-substance behavioral dependence.<\/li>\n<li><em>Conditional Clinical Scoring:<\/em> Administered conditionally only to individuals who have reported lifetime or past-year use of the targeted substance, isolating true dependence risk among actual consumers.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h2>11. Permissions &#038; Fee and Test Year<\/h2>\n<p>The Monitoring the Future Survey\/Dependency Scale was developed in <strong>2001<\/strong> as part of the ongoing national research series sponsored by the <a href=\"https:\/\/nida.nih.gov\/\" target=\"_blank\" rel=\"noopener noreferrer\">National Institute on Drug Abuse<\/a> (NIDA Grant Numbers R01 DA 001411 and R01 DA 016511). As an instrument developed under federal research grants and published within public epidemiological reports and government recommendations (e.g., the Center for Substance Abuse Prevention Core Measures Initiative), the core survey items reside within the <strong>public domain<\/strong>.<\/p>\n<p>Researchers, public health officials, and clinical practitioners may freely utilize the scale without royalty fees or formal licensing charges. However, academic integrity mandates that proper bibliographic citation be provided to the principal investigators and the Institute for Social Research at the University of Michigan. Any alteration of item phrasing, translation into alternative languages, or commercial packaging requires acknowledgment of the original source.<\/p>\n<h2>12. References<\/h2>\n<ul>\n<li>American Psychiatric Association. (2013). <em>Diagnostic and statistical manual of mental disorders<\/em> (5th ed.). American Psychiatric Publishing. <a href=\"https:\/\/doi.org\/10.1176\/appi.books.9780890425596\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/doi.org\/10.1176\/appi.books.9780890425596<\/a><\/li>\n<li>Edwards, G., &amp; Gross, M. M. (1976). Alcohol dependence: Provisional description of a clinical syndrome. <em>British Medical Journal<\/em>, 1(6017), 1058\u20131061. <a href=\"https:\/\/doi.org\/10.1136\/bmj.1.6017.1058\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/doi.org\/10.1136\/bmj.1.6017.1058<\/a><\/li>\n<li>Johnston, L. D., O\u2019Malley, P. M., &amp; Bachman, J. G. (2001). <em>Monitoring the Future national survey results on drug use, 1975\u20132000: Volume I, Secondary school students<\/em> (NIH Publication No. 01-4924). National Institute on Drug Abuse.<\/li>\n<li>Johnston, L. D., O\u2019Malley, P. M., Miech, R. A., Bachman, J. G., &amp; Schulenberg, J. E. (2015). <em>Monitoring the Future national survey results on drug use: 1975\u20132014: Overview, key findings on adolescent drug use<\/em>. Institute for Social Research, The University of Michigan. <a href=\"https:\/\/files.eric.ed.gov\/fulltext\/ED558514.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/files.eric.ed.gov\/fulltext\/ED558514.pdf<\/a><\/li>\n<li>Miech, R. A., Johnston, L. D., O\u2019Malley, P. M., Bachman, J. G., Schulenberg, J. E., &amp; Patrick, M. E. (2022). <em>Monitoring the Future national survey results on drug use, 1975\u20132021: Volume I, Secondary school students<\/em>. Institute for Social Research, The University of Michigan. <a href=\"https:\/\/doi.org\/10.3998\/2027.42\/174981\" target=\"_blank\" rel=\"noopener noreferrer\">https:\/\/doi.org\/10.3998\/2027.42\/174981<\/a><\/li>\n<li>Substance Abuse and Mental Health Services Administration (SAMHSA) \/ Center for Substance Abuse Prevention (CSAP). (2001). <em>Core Measures Initiative Phase I Recommendations<\/em> (pp. 34\u201335, 38\u201340). U.S. Department of Health and Human Services.<\/li>\n<\/ul>\n<h2>13. Items of the Scale<\/h2>\n<div class=\"wpt-scale-items-container\" style=\"direction:ltr; text-align:left; font-family:sans-serif;\">\n<p>The following questions represent the exact 6-item inventory comprising the Monitoring the Future Dependency Scale. Respondents are instructed to evaluate their lifetime attempts at cessation or moderation for each specific substance.<\/p>\n<div style=\"margin-bottom:20px; padding:12px; background:#f9f9f9; border:1px solid #e0e0e0; border-radius:4px;\">\n<p style=\"font-weight:600; margin-bottom:8px;\">1. Was there ever a time in your life when you tried to quit using cigarettes or reduce your use and had difficulty doing so?<\/p>\n<ul style=\"list-style:none; padding-left:15px; margin:0;\">\n<li>8. Never used<\/li>\n<li>1. No<\/li>\n<li>2. Yes<\/li>\n<\/ul><\/div>\n<div style=\"margin-bottom:20px; padding:12px; background:#f9f9f9; border:1px solid #e0e0e0; border-radius:4px;\">\n<p style=\"font-weight:600; margin-bottom:8px;\">2. Was there ever a time in your life when you tried to quit using alcohol or reduce your use and had difficulty doing so?<\/p>\n<ul style=\"list-style:none; padding-left:15px; margin:0;\">\n<li>8. Never used<\/li>\n<li>1. No<\/li>\n<li>2. Yes<\/li>\n<\/ul><\/div>\n<div style=\"margin-bottom:20px; padding:12px; background:#f9f9f9; border:1px solid #e0e0e0; border-radius:4px;\">\n<p style=\"font-weight:600; margin-bottom:8px;\">3. Was there ever a time in your life when you tried to quit using marijuana or reduce your use and had difficulty doing so?<\/p>\n<ul style=\"list-style:none; padding-left:15px; margin:0;\">\n<li>8. Never used<\/li>\n<li>1. No<\/li>\n<li>2. Yes<\/li>\n<\/ul><\/div>\n<div style=\"margin-bottom:20px; padding:12px; background:#f9f9f9; border:1px solid #e0e0e0; border-radius:4px;\">\n<p style=\"font-weight:600; margin-bottom:8px;\">4. Was there ever a time in your life when you tried to quit using cocaine (&#8220;crack,&#8221; powder, etc.) or reduce your use and had difficulty doing so?<\/p>\n<ul style=\"list-style:none; padding-left:15px; margin:0;\">\n<li>8. Never used<\/li>\n<li>1. No<\/li>\n<li>2. Yes<\/li>\n<\/ul><\/div>\n<div style=\"margin-bottom:20px; padding:12px; background:#f9f9f9; border:1px solid #e0e0e0; border-radius:4px;\">\n<p style=\"font-weight:600; margin-bottom:8px;\">5. Was there ever a time in your life when you tried to quit using heroin or reduce your use and had difficulty doing so?<\/p>\n<ul style=\"list-style:none; padding-left:15px; margin:0;\">\n<li>8. Never used<\/li>\n<li>1. No<\/li>\n<li>2. Yes<\/li>\n<\/ul><\/div>\n<div style=\"margin-bottom:20px; padding:12px; background:#f9f9f9; border:1px solid #e0e0e0; border-radius:4px;\">\n<p style=\"font-weight:600; margin-bottom:8px;\">6. Was there ever a time in your life when you tried to quit using any other illegal drugs or reduce your use and had difficulty doing so?<\/p>\n<ul style=\"list-style:none; padding-left:15px; margin:0;\">\n<li>8. Never used<\/li>\n<li>1. No<\/li>\n<li>2. Yes<\/li>\n<\/ul><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A comprehensive psychometric review of the Monitoring the Future Survey\/Dependency Scale, examining its construct validity, factor structure, reliability, and items assessing impaired behavioral control over substance use.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","categories":[66,2,12791],"tags":[1928,12793,4559,12794,12776,6,12792],"class_list":["post-3540","psych_scale","type-psych_scale","status-publish","hentry","category-clinical-psychology","category-psychometrics","category-substance-use-measures","tag-addiction-screening","tag-adolescent-substance-use","tag-epidemiology","tag-impaired-control","tag-monitoring-the-future","tag-psychometrics","tag-substance-dependence"],"_links":{"self":[{"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/psych_scale\/3540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/psych_scale"}],"about":[{"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/types\/psych_scale"}],"author":[{"embeddable":true,"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ashadocs.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3540"}],"version-history":[{"count":0,"href":"https:\/\/ashadocs.org\/index.php?rest_route=\/wp\/v2\/psych_scale\/3540\/revisions"}],"wp:attachment":[{"href":"https:\/\/ashadocs.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ashadocs.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ashadocs.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}